Literature DB >> 22281290

Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro".

Erica Mie Akagi1, Paulo Luiz de Sá Júnior, Simone Michaela Simons, Maria Helena Bellini, Sandra Alves Barreto, Ana Marisa Chudzinski-Tavassi.   

Abstract

Renal cell carcinoma (RCC) is one of the most lethal urologic cancers and is highly resistant to both radiotherapy and chemotherapy. The recombinant protein Amblyomin-X, characterized as a Kunitz-type protease inhibitor, was obtained from a cDNA library from the salivary glands of the Amblyomma cajennense tick. This paper reports the biological effect of Amblyomin-X on inducing cell death by apoptotic process in vitro. For this purpose, the changes in morphological aspects of cells, the phosphatidylserine exposition and DNA degradation were evaluated after treatment with Amblyomin-X. We found that Amblyomin-X was able to induce apoptosis in Renca cells in a dose-dependent manner. So, the results presented here open perspectives for new researches and developing for Amblyomin-X in the treatment of RCC.
© 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22281290     DOI： 10.1016/j.biopha.2011.11.015

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


  7 in total

1.  A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.

Authors:  Durvanei Augusto Maria; Jean Gabriel de Souza; Katia L P Morais; Carolina Maria Berra; Hamilton de Campos Zampolli; Marilene Demasi; Simone Michaela Simons; Renata de Freitas Saito; Roger Chammas; Ana Marisa Chudzinski-Tavassi
Journal:  Invest New Drugs       Date:  2012-09-14       Impact factor: 3.850

2.  Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.

Authors:  Mario T F Pacheco; Carolina M Berra; Kátia L P Morais; Juliana M Sciani; Vania G Branco; Rosemary V Bosch; Ana M Chudzinski-Tavassi
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

3.  New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X.

Authors:  Lorena Favaro Pavon; David Capper; Tatiana Tais Sibov; Silvia Regina Caminada de Toledo; Ulrich-W Thomale; Jean Gabriel de Souza; Francisco Romero Cabral; Carolina Maria Berra; Marcos Devanir Silva da Costa; Jardel Mendonça Niçacio; Patrícia Alessandra Dastoli; Daniela Mara de Oliveira; Suzana M F Malheiros; Edgar Ferreira da Cruz; Jackeline Moraes Malheiros; Sérgio Mascarenhas de Oliveira; Nasjla Saba Silva; Antonio Sérgio Petrilli; Andrea Maria Cappellano; Milena Colò Brunialti; Reinaldo Salomão; Manoel A de Paiva Neto; Ana Marisa Chudzinski-Tavassi; Sérgio Cavalheiro
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

Review 4.  Insights into the Role of Tick Salivary Protease Inhibitors during Ectoparasite-Host Crosstalk.

Authors:  Mohamed Amine Jmel; Hajer Aounallah; Chaima Bensaoud; Imen Mekki; Jindřich Chmelař; Fernanda Faria; Youmna M'ghirbi; Michalis Kotsyfakis
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

Review 5.  A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate.

Authors:  Aline R M Lobba; Miryam Paola Alvarez-Flores; Melissa Regina Fessel; Marcus Vinicius Buri; Douglas S Oliveira; Renata N Gomes; Priscila S Cunegundes; Carlos DeOcesano-Pereira; Victor D Cinel; Ana M Chudzinski-Tavassi
Journal:  Front Mol Biosci       Date:  2022-08-16

6.  Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.

Authors:  Jean Gabriel de Souza; Katia L.P. Morais; Eduardo Anglés-Cano; Pamela Boufleur; Evandro Sobroza de Mello; Durvanei Augusto Maria; Clarice Silvia Taemi Origassa; Hamilton de Campos Zampolli; Niels Olsen Saraiva Câmara; Carolina Maria Berra; Rosemary Viola Bosch; Ana Marisa Chudzinski-Tavassi
Journal:  Oncotarget       Date:  2016-09-20

7.  Modulation of stress and immune response by Amblyomin-X results in tumor cell death in a horse melanoma model.

Authors:  Flavio Lichtenstein; Asif Iqbal; Sonia Elisabete Alves de Lima Will; Rosemary Viola Bosch; Carlos DeOcesano-Pereira; Mauricio Barbugiani Goldfeder; Roger Chammas; Carlos Eduardo Madureira Trufen; Katia Luciano Pereira Morais; Jean Gabriel de Souza; Renato Jose Mendonça Natalino; Inacio Junqueira de Azevedo; Milton Yutaka Nishiyama Junior; Ursula Oliveira; Francisco Ivanio Arruda Alves; Jaqueline Mayara Araujo; Aline Ramos Maia Lobba; Ana Marisa Chudzinski-Tavassi
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.